DEVON, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the underwriters of its previously announced public offering of 2.8 million shares of its common stock have exercised in full their option to purchase an additional […]

by

After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor. In the phase 2 study, the U.K. biopharma’s cannabidiol (CBD) and tetrahydrocannabinol (THC) candidate, both of which are active ingredients derived from cannabis, showed […]

by

Many parents come to my office seeking help for their children suffering with autism.   The three main symptoms that are challenging for these families are communication difficulties, repetitive behaviors, and social challenges, including tantrums and self-injurious behavior.  Although the FDA has approved two medications, both antipsychotics, for treating the irritability associated with autism, they have […]

by

DEVON, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the underwriters of its previously announced public offering of 2.8 million shares of its common stock have exercised in full their option to purchase an additional […]

by

LONDON, Feb. 08, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February […]

by

DES MOINES — Caleb Helland, when he was 10 years old, was having roughly 10 atonic, or “head-drop,” seizures as a result of his intractable epilepsy. After two weeks of cannabis oil treatments, the Mason City boy’s atonic seizures stopped completely and never returned, his mother said. That was roughly a year-and-a-half ago. “He’s way […]

by

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine. Risk Mitigation Through Diversification The company announced Tuesday positive top-line results from a mid-stage placebo-controlled study of a proprietary combination of tetrahydrocannabinol, or THC, and cannabidiol, […]

by

LONDON, Feb. 08, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February […]

by

– Epidiolex® NDA submission and launch preparation on track –– New Positive Phase 2 glioma data further demonstrates value of cannabinoid pipeline – – Conference call today at 8:30 a.m. EST – LONDON, Feb. 07, 2017 — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing […]

by

GW intends to advance oncology research and development efforts London (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a […]

by

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused… read more at: https://www.newcannabisventures.com/gw-pharma-reports-success-in-brain-cancer-phase-2-clinical-trial/

by